Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Shares Outstanding (Weighted Average) (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Shares Outstanding (Weighted Average) for 8 consecutive years, with $61.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 128.96% to $61.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $61.9 million through Dec 2025, up 128.96% year-over-year, with the annual reading at $61.9 million for FY2025, 128.96% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $61.9 million at Whitehawk Therapeutics, up from $59.4 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $69.1 million in Q2 2025, with the low at $29166.0 in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $24.3 million, with a median of $24.7 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) crashed 99.94% in 2022, then skyrocketed 92612.06% in 2024.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $36666.0 in 2021, then soared by 61295.4% to $22.5 million in 2022, then plummeted by 99.87% to $29167.0 in 2023, then skyrocketed by 92573.03% to $27.0 million in 2024, then skyrocketed by 128.96% to $61.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $61.9 million, $59.4 million, and $69.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.